In the management of diabetes and CKD, interdisciplinary therapies that target critical pathophysiological pathways, such as angiotensin-converting enzyme (ACE) inhibitors, sodium-glucose cotransporter-2 (SGLT2) inhibitors, and mineralocorticoid receptor antagonists (MRAs), have been proposed and proven efficacious. The gene discussed is ACE; the disease is chronic kidney disease.